OR WAIT 15 SECS
Neovacs acquired Amegabiotech’s Interferon Alpha manufacturing license for the manufacture of its lead therapeutic candidate.
On Nov. 15, 2016 Neovacs announced an agreement with the Argentinean company Amegabiotech to acquire its Interferon Alpha (IFNα) manufacturing license. IFNα is a key component of Neovacs’ lead therapeutic candidate, IFNα Kinoid, which is composed of inactivated IFNα coupled with a carrier protein, keyhole limpet hemocyanin. According to Neovacs, the acquisition significantly strengthens the company’s commercialization strategy of the IFNα Kinoid therapeutic vaccine for lupus.
Amegabiotech is a producer of IFNα protein and a long-term supplier of Neovacs, particularly for its on-going Phase IIb study of IFNα Kinoid in lupus. Their product is recognized by the international biotechnology and pharmaceutical industry for the quality of its technological manufacturing, which also meets all relevant international GMP standards.